US Patent 11834458 Anti-cancer nuclear hormone receptor-targeting compounds
Patent 11834458 was granted and assigned to Nuvation Bio on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+37 properties)
Article (+194 characters)
US Patent 11834458 Anti-cancer nuclear hormone receptor-targeting compounds
Article
Patent abstract
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Christopher Paul Miller0
David Hung0
Ihab S. Darwish0
Jayakanth Kankanala0
Jeremy David Pettigrew0
Son Minh Pham0
Date of Patent
December 5, 2023
0Patent Application Number
177014250
Date Filed
March 22, 2022
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11834458 Anti-cancer nuclear hormone receptor-targeting compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.